Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider

Javier Rodríguez‐Carrio(Universidad de Oviedo), Marjan A. Versnel(Erasmus MC)

RMD Open

March 1, 2023

10.1136/rmdopen-2022-002864

Cited by 38

Related Papers

Amlexanox inhibits production of type I interferon and suppresses B cell differentiation <i>in vitro</i>: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases

|RMD Open|2025|2